非識別化健康データの世界市場規模、シェア、動向分析レポート：データタイプ別、用途別、最終用途別、地域別、セグメント別予測（2025年～2030年）

非識別化健康データ市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の非識別化健康データの市場規模は、2025年～2030年にCAGR9.07％を記録し、2030年までに135億9,000万米ドルに達する見込みです。

同市場の成長の主な原動力は、ヘルスケアにおけるデータ分析需要の高まりであり、患者のプライバシーを確保しつつ、集団健康調査や予測モデリングをサポートします。データ保護をめぐる規制圧力の高まりは、AIや機械学習の進歩と相まって、大規模な非識別化データセットのニーズの高まりを生み出しています。さらに、ウェアラブルや電子カルテ（EHR）からのデータの急増は、非識別化と二次利用に適した大量の情報を生み出し、市場の需要をさらに押し上げています。

非識別化されたデータは、薬局や医療保険への患者の加入に関連するパターンを分析することによって、保険の状態に関する洞察を導き出すために利用されます。このデータにより、企業はプライバシーを損なうことなく、一次および二次支払者の特定、保険動向の評価、患者の属性把握が可能になります。例えば、2024年6月、Komodo HealthはKomodo Patient Insurance（KPI）を発表しました。この斬新なデータ提供により、2億人を超える米国患者の保険状況を詳細に把握することができます。このリソースは、患者の薬局および医療保険への加入状況を正確に特定し、さまざまなチャネル、セグメント、地域にわたる一次および二次支払者情報を詳述します。このKPIは、コマーシャル、マーケット・アクセス、メディカル・アフェアーズ、医療経済・アウトカム・リサーチ（HEOR）の各チームが、患者登録と支払者マッピングに関連する主要なビジネス上の疑問に効率的に対処するのに役立ちます。

さらに、主要な市場参入企業間の提携と協力の拡大が市場成長を促進すると予想されます。例えば、2024年3月、Verantosは、臨床研究における非識別化健康データの活用を強化するため、Curimetaとの提携を発表しました。この提携は、強固なデータ非識別化プロセスを通じて患者のプライバシーを確保しながら、実世界でのエビデンス生成を改善することに焦点を当てています。キュリメタのデータサイエンス能力とベラントスの実データに関する専門知識を活用することで、このパートナーシップは、ヘルスケアのイノベーションを推進し、患者の転帰を改善する貴重な洞察を提供することを目指しています。非識別化データを重視することは、安全なデータ共有と規制基準の遵守を促進する上で極めて重要です。

「Verantos Evidence Platformは、人工知能（AI）を使用して、疾患特有の洞察を生み出します。AIモデルは、高品質の患者ケアデータを使用してトレーニングされることが重要です。CuriMetaの参加により、ライフサイエンス研究を加速させるために使用される疾患特有のプラグマティック登録の強化が可能になります。」

アナンド・シュロフ、Verantos社長

非識別化健康データ市場レポートのハイライト

• データタイプ別では、臨床データセグメントが2024年のシェアで約17.0%を占め、市場を独占しています。このセグメントの優位性は、研究、治療開発、患者ケアの最適化において重要な役割を果たすことに起因しています。
• 用途別では、臨床研究・臨床試験セグメントが2024年に最大の収益シェアを占めました。これは、治療法の進歩、医療機器の革新、患者の安全性において重要な役割を果たすことに起因します。
• 最終用途別では、ヘルスケア提供者セグメントが2024年に最大の収益シェアを占めました。ヘルスケア提供者セグメントは、臨床的意思決定、治療の最適化、患者の転帰改善において重要な役割を果たすため、市場をリードしています。
• 北米は2024年の売上高シェア31.53%で市場を独占しました。同地域は先進的なヘルスケアインフラを有し、特にデータ分析とAIに多額の技術投資を行っています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 非識別化健康データ市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
• 非識別化健康データ市場の分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響

第4章 非識別化健康データ市場：データタイプの推定・動向分析

• 市場シェア（2024年・2030年）：データタイプ別
• セグメントダッシュボード
• 世界の非識別化健康データ市場の展望：データタイプ別
• 臨床データ
• ゲノムデータ
• 患者の人口統計
• 処方データ
• クレームデータ
• 行動データ
• ウェアラブルとセンサーデータ
• 調査と患者報告データ
• 画像データ
• 検査データ
• 病院と提供者のデータ
• 健康の社会的決定要因（SDoH）データ
• 薬理ゲノムデータ
• 生体認証データ
• 運用および財務データ
• 疫学データ
• ヘルスケア利用データ
• その他

第5章 非識別化健康データ市場：最終用途の推定・動向分析

• 市場シェア（2024年・2030年）：最終用途別
• セグメントダッシュボード
• 世界の非識別化健康データ市場の展望：最終用途別
• 製薬会社
• バイオテクノロジー企業
• 医療機器メーカー
• ヘルスケア提供者
• 保険会社/ヘルスケア支払者
• 研究機関
• 政府機関
• その他

第6章 非識別化健康データ市場：用途の推定・動向分析

• 市場シェア（2024年・2030年）：用途別
• セグメントダッシュボード
• 世界の非識別化健康データ市場の展望：用途別
• 臨床研究と治験
• 公衆衛生
• 精密医療
• 医療経済とアウトカム研究（HEOR）
• 人口健康管理
• 医薬品の創薬と開発
• ヘルスケアの質の向上
• 保険引受とリスク評価
• 市場アクセスと商業戦略
• ビジネスインテリジェンスと運用効率
• 遠隔医療と遠隔モニタリング
• 患者エンゲージメントおよびサポートプログラム
• その他

第7章 非識別化健康データ市場：地域の推定・動向分析、データタイプ別、最終用途別、用途別

• 地域別の市場シェア分析（2024年・2030年）
• 地域市場ダッシュボード
• 世界の地域市場スナップショット
• 市場規模と予測動向分析（2018年～2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• イノベーター
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析：2024年
  • IQVIA
  • Oracle（Cerner Corporation）
  • Merative（Truven Health Analytics）
  • Optum, Inc.（UnitedHealth Group）
  • ICON plc
  • Veradigm LLC（Formerly known as Allscripts）
  • IBM
  • Flatiron Health（F. Hoffmann-La Roche Ltd）
  • Premier, Inc.
  • Shaip
  • Komodo Health, Inc.
  • Evidation Health, Inc.
  • Medidata
  • Clarify Health Solutions
  • Satori Cyber Ltd.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America de-identified health data market, by region, 2018 - 2030 (USD Million)
• Table 3 North America de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 4 North America de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 5 North America de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 7 U.S. de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 8 U.S. de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 9 Canada de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 10 Canada de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 11 Canada de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 12 Mexico de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 13 Mexico de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 14 Mexico de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 15 Europe de-identified health data market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 17 Europe de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 18 Europe de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 19 Germany de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 20 Germany de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 21 Germany de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 22 UK de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 23 UK de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 24 UK de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 25 France de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 26 France de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 27 France de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 28 Italy de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 29 Italy de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 30 Italy de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 31 Spain de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 32 Spain de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 33 Spain de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 34 Denmark de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 35 Denmark de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 36 Denmark de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 37 Sweden de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 38 Sweden de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 39 Sweden de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 40 Norway de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 41 Norway de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 42 Norway de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific de-identified health data market, by region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 47 China de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 48 China de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 49 China de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 50 Japan de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 51 Japan de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 52 Japan de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 53 India de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 54 India de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 55 India de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 56 South Korea de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 57 South Korea de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 58 South Korea de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 59 Australia de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 60 Australia de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 61 Australia de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 62 Thailand de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 63 Thailand de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 64 Thailand de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 65 Latin America de-identified health data market, by region, 2018 - 2030 (USD Million)
• Table 66 Latin America de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 67 Latin America de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 68 Latin America de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 69 Brazil de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 70 Brazil de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 71 Brazil de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 72 Argentina de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 73 Argentina de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 74 Argentina de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 75 MEA de-identified health data market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 77 MEA de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 78 MEA de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 79 South Africa de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 80 South Africa de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 81 South Africa de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 85 UAE de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 86 UAE de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 87 UAE de-identified health data market, by application, 2018 - 2030 (USD Million)
• Table 88 Kuwait de-identified health data market, by type of data, 2018 - 2030 (USD Million)
• Table 89 Kuwait de-identified health data market, by end use, 2018 - 2030 (USD Million)
• Table 90 Kuwait de-identified health data market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 De-identified Health Data market: market outlook
• Fig. 9 De-identified Health Data competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 De-identified Health Data market driver impact
• Fig. 15 De-identified Health Data market restraint impact
• Fig. 16 De-identified Health Data market strategic initiatives analysis
• Fig. 17 De-identified Health Data market: Type of Data movement analysis
• Fig. 18 De-identified Health Data market: Type of Data outlook and key takeaways
• Fig. 19 Clinical data market estimates and forecast, 2018 - 2030
• Fig. 20 Genomic data market estimates and forecast, 2018 - 2030
• Fig. 21 Patient demographics market estimates and forecast, 2018 - 2030
• Fig. 22 Prescription data market estimates and forecast, 2018 - 2030
• Fig. 23 Claims data market estimates and forecast, 2018 - 2030
• Fig. 24 Behavioral data market estimates and forecast, 2018 - 2030
• Fig. 25 Wearable and sensor data market estimates and forecast, 2018 - 2030
• Fig. 26 Survey and patient-reported data market estimates and forecast, 2018 - 2030
• Fig. 27 Imaging data market estimates and forecast, 2018 - 2030
• Fig. 28 Laboratory data market estimates and forecast, 2018 - 2030
• Fig. 29 Hospital and provider data market estimates and forecast, 2018 - 2030
• Fig. 30 Social determinants of health (SDoH) data market estimates and forecast, 2018 - 2030
• Fig. 31 Pharmacogenomic data market estimates and forecast, 2018 - 2030
• Fig. 32 Biometric data market estimates and forecast, 2018 - 2030
• Fig. 33 Operational and financial data market estimates and forecast, 2018 - 2030
• Fig. 34 Epidemiological data market estimates and forecast, 2018 - 2030
• Fig. 35 Healthcare utilization data market estimates and forecast, 2018 - 2030
• Fig. 36 Others market estimates and forecast, 2018 - 2030
• Fig. 37 De-identified Health Data market: End use analysis
• Fig. 38 De-identified Health Data market: End use outlook and key takeaways
• Fig. 39 Pharmaceutical companies market estimates and forecast, 2018 - 2030
• Fig. 40 Biotechnology firms market estimates and forecast, 2018 - 2030
• Fig. 41 Medical device manufacturers market estimates and forecast, 2018 - 2030
• Fig. 42 Healthcare providers market estimates and forecast, 2018 - 2030
• Fig. 43 Insurance companies/ Healthcare payers market estimates and forecast, 2018 - 2030
• Fig. 44 Research institutions market estimates and forecast, 2018 - 2030
• Fig. 45 Government agencies market estimates and forecast, 2018 - 2030
• Fig. 46 Others market estimates and forecast, 2018 - 2030
• Fig. 47 De-identified Health Data market: Application movement analysis
• Fig. 48 De-identified Health Data market: Application outlook and key takeaways
• Fig. 49 Clinical research and trials market estimates and forecast, 2018 - 2030
• Fig. 50 Public health market estimates and forecast, 2018 - 2030
• Fig. 51 Precision medicine market estimates and forecast, 2018 - 2030
• Fig. 52 Health economics and outcomes research (HEOR) market estimates and forecast, 2018 - 2030
• Fig. 53 Population health management market estimates and forecast, 2018 - 2030
• Fig. 54 Drug discovery and development market estimates and forecast, 2018 - 2030
• Fig. 55 Healthcare quality improvement market estimates and forecast, 2018 - 2030
• Fig. 56 Insurance underwriting and risk assessment market estimates and forecast, 2018 - 2030
• Fig. 57 Market access and commercial strategy market estimates and forecast, 2018 - 2030
• Fig. 58 Business intelligence and operational efficiency market estimates and forecast, 2018 - 2030
• Fig. 59 Telemedicine and remote monitoring market estimates and forecast, 2018 - 2030
• Fig. 60 Patient engagement and support programs market estimates and forecast, 2018 - 2030
• Fig. 61 Others market estimates and forecast, 2018 - 2030
• Fig. 62 Global de-identified health data market: Regional movement analysis
• Fig. 63 Global de-identified health data market: Regional outlook and key takeaways
• Fig. 64 Global de-identified health data market share and leading players
• Fig. 65 North America market share and leading players
• Fig. 66 Europe market share and leading players
• Fig. 67 Asia Pacific market share and leading players
• Fig. 68 Latin America market share and leading players
• Fig. 69 Middle East & Africa market share and leading players
• Fig. 70 North America: SWOT
• Fig. 71 Europe SWOT
• Fig. 72 Asia Pacific SWOT
• Fig. 73 Latin America SWOT
• Fig. 74 MEA SWOT
• Fig. 75 North America, by country
• Fig. 76 North America
• Fig. 77 North America market estimates and forecasts, 2018 - 2030
• Fig. 78 U.S. key country dynamics
• Fig. 79 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 80 Canada key country dynamics
• Fig. 81 Canada market estimates and forecasts, 2018 - 2030
• Fig. 82 Mexico key country dynamics
• Fig. 83 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 84 Europe
• Fig. 85 Europe market estimates and forecasts, 2018 - 2030
• Fig. 86 UK key country dynamics
• Fig. 87 UK market estimates and forecasts, 2018 - 2030
• Fig. 88 Germany key country dynamics
• Fig. 89 Germany market estimates and forecasts, 2018 - 2030
• Fig. 90 France key country dynamics
• Fig. 91 France market estimates and forecasts, 2018 - 2030
• Fig. 92 Italy key country dynamics
• Fig. 93 Italy market estimates and forecasts, 2018 - 2030
• Fig. 94 Spain key country dynamics
• Fig. 95 Spain market estimates and forecasts, 2018 - 2030
• Fig. 96 Denmark key country dynamics
• Fig. 97 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 98 Sweden key country dynamics
• Fig. 99 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 100 Norway key country dynamics
• Fig. 101 Norway market estimates and forecasts, 2018 - 2030
• Fig. 102 Asia Pacific
• Fig. 103 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 104 China key country dynamics
• Fig. 105 China market estimates and forecasts, 2018 - 2030
• Fig. 106 Japan key country dynamics
• Fig. 107 Japan market estimates and forecasts, 2018 - 2030
• Fig. 108 India key country dynamics
• Fig. 109 India market estimates and forecasts, 2018 - 2030
• Fig. 110 Thailand key country dynamics
• Fig. 111 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 112 South Korea key country dynamics
• Fig. 113 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 114 Australia key country dynamics
• Fig. 115 Australia market estimates and forecasts, 2018 - 2030
• Fig. 116 Latin America
• Fig. 117 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 118 Brazil key country dynamics
• Fig. 119 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 120 Argentina key country dynamics
• Fig. 121 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 122 Middle East and Africa
• Fig. 123 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 124 South Africa key country dynamics
• Fig. 125 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 126 Saudi Arabia key country dynamics
• Fig. 127 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 128 UAE key country dynamics
• Fig. 129 UAE market estimates and forecasts, 2018 - 2030
• Fig. 130 Kuwait key country dynamics
• Fig. 131 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 132 Market share of key market players- de-identified health data market

De-identified Health Data Market Growth & Trends:

The global de-identified health data market size is expected to reach USD 13.59 billion by 2030, registering a CAGR of 9.07% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market's growth is primarily driven by the rising demand for data analytics in healthcare, which supports population health studies and predictive modeling while ensuring patient privacy. Increasing regulatory pressure surrounding data protection, combined with AI and machine learning advancements, is creating a growing need for large-scale, de-identified datasets. In addition, the surge in data from wearables and electronic health records (EHRs) generates substantial volumes of information suitable for de-identification and secondary use, further boosting market demand.

De-identified data is utilized to derive insights into insurance status by analyzing patterns related to patient enrollment in pharmacy and medical insurance. This data enables organizations to identify primary and secondary payers, assess coverage trends, and understand patient demographics without compromising privacy. For instance, in June 2024, Komodo Health introduced the Komodo Patient Insurance (KPI). This novel data offering provides detailed insights into the insurance status of over 200 million de-identified U.S. patients. This resource accurately identifies patients' pharmacy and medical insurance enrollment, detailing primary and secondary payer information across various channels, segments, and geographies. The KPI will assist Commercial, Market Access, Medical Affairs, and Health Economics and Outcomes Research (HEOR) teams in efficiently addressing key business questions related to patient enrollment and payer mapping.

Moreover, the increasing partnership and collaboration among the key market players are expected to drive market growth. For instance, in March 2024, Verantos announced a partnership with Curimeta to enhance the utilization of de-identified health data in clinical research. This collaboration focuses on improving real-world evidence generation while ensuring patient privacy through robust data de-identification processes. By leveraging Curimeta's data science capabilities and Verantos' expertise in real-world data, the partnership aims to provide valuable insights that can drive healthcare innovations and improve patient outcomes. The emphasis on de-identified data is crucial for facilitating secure data sharing and compliance with regulatory standards.

"The Verantos Evidence Platform uses artificial intelligence (AI) to generate unique disease-specific insights. It is critical that AI models are trained using high-quality patient care data. CuriMeta's participation will enable us to enhance our disease-specific Pragmatic Registries that are used to accelerate life sciences research."

Anand Shroff, President of Verantos

De-identified Health Data Market Report Highlights:

• Based on the type of data, the clinical data segment dominated the market with almost 17.0% of the share in 2024. The segment's dominance is attributed to its crucial role in research, treatment development, and patient care optimization.
• Based on application, the clinical research and trials segment held the largest revenue share in 2024. This is attributed to its key role in advancing treatment methods, medical device innovation, and patient safety.
• Based on the end-use, the healthcare providers segment held the largest revenue share in 2024. The healthcare providers segment leads the market owing to its crucial role in clinical decision-making, treatment optimization, and patient outcome improvement.
• North America dominated the market with a revenue share of 31.53% in 2024. The region has an advanced healthcare infrastructure and significant technological investment, particularly in data analytics and AI.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type of data
  • 1.1.2. End use
  • 1.1.3. Application
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type of data outlook
  • 2.2.2. End use outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. De-identified Health Data Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market Opportunity analysis
• 3.3. De-identified Health Data Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
  • 3.3.3. COVID-19 Impact

Chapter 4. De-identified Health Data Market: Type of Data Estimates & Trend Analysis

• 4.1. Type of Data Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global De-identified Health Data Market by Type of Data Outlook
• 4.4. Clinical Data
  • 4.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.5. Genomic Data
  • 4.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.6. Patient Demographics
  • 4.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.7. Prescription Data
  • 4.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.8. Claims Data
  • 4.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.9. Behavioral Data
  • 4.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.10. Wearable and Sensor Data
  • 4.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.11. Survey and Patient-Reported Data
  • 4.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.12. Imaging Data
  • 4.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.13. Laboratory Data
  • 4.13.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.14. Hospital and Provider Data
  • 4.14.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.15. Social Determinants of Health (SDoH) Data
  • 4.15.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.16. Pharmacogenomic Data
  • 4.16.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.17. Biometric Data
  • 4.17.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.18. Operational and Financial Data
  • 4.18.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.19. Epidemiological Data
  • 4.19.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.20. Healthcare Utilization Data
  • 4.20.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 4.21. Others
  • 4.21.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 5. De-identified Health Data Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global De-identified Health Data Market by End Use Outlook
• 5.4. Pharmaceutical Companies
  • 5.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.5. Biotechnology Firms
  • 5.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.6. Medical Device Manufacturers
  • 5.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.7. Healthcare Providers
  • 5.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.8. Insurance Companies/ Healthcare Payers
  • 5.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.9. Research Institutions
  • 5.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.10. Government Agencies
  • 5.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 6. De-identified Health Data Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global De-identified Health Data Market by Application Outlook
• 6.4. Clinical Research and Trials
  • 6.4.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.5. Public Health
  • 6.5.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.6. Precision Medicine
  • 6.6.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.7. Health Economics and Outcomes Research (HEOR)
  • 6.7.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.8. Population Health Management
  • 6.8.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.9. Drug Discovery and Development
  • 6.9.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.10. Healthcare Quality Improvement
  • 6.10.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.11. Insurance Underwriting and Risk Assessment
  • 6.11.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.12. Market Access and Commercial Strategy
  • 6.12.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.13. Business Intelligence and Operational Efficiency
  • 6.13.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.14. Telemedicine and Remote Monitoring
  • 6.14.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.15. Patient Engagement and Support Programs
  • 6.15.1. Market estimates and forecast 2018 - 2030 (USD Million)
• 6.16. Others
  • 6.16.1. Market estimates and forecast 2018 - 2030 (USD Million)

Chapter 7. De-identified Health Data Market: Regional Estimates & Trend Analysis, By Type of Data, By End use, By Application

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 - 2030
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Singapore market estimates and forecasts 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Innovators
• 8.4. Vendor Landscape
  • 8.4.1. List of key distributors and channel partners
  • 8.4.2. Key customers
  • 8.4.3. Key company market share analysis, 2024
  • 8.4.4. IQVIA
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Technology Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Oracle (Cerner Corporation)
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Technology Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Merative (Truven Health Analytics)
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Technology Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Optum, Inc. (UnitedHealth Group)
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Technology Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. ICON plc
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Technology Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Veradigm LLC (Formerly known as Allscripts)
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Technology Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. IBM
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Technology Type benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Flatiron Health (F. Hoffmann-La Roche Ltd)
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Technology Type benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Premier, Inc.
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Technology Type benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Shaip
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Technology Type benchmarking
    • 8.4.13.4. Strategic initiatives
  • 8.4.14. Komodo Health, Inc.
    • 8.4.14.1. Company overview
    • 8.4.14.2. Financial performance
    • 8.4.14.3. Technology Type benchmarking
    • 8.4.14.4. Strategic initiatives
  • 8.4.15. Evidation Health, Inc.
    • 8.4.15.1. Company overview
    • 8.4.15.2. Financial performance
    • 8.4.15.3. Technology Type benchmarking
    • 8.4.15.4. Strategic initiatives
  • 8.4.16. Medidata
    • 8.4.16.1. Company overview
    • 8.4.16.2. Financial performance
    • 8.4.16.3. Technology Type benchmarking
    • 8.4.16.4. Strategic initiatives
  • 8.4.17. Clarify Health Solutions
    • 8.4.17.1. Company overview
    • 8.4.17.2. Financial performance
    • 8.4.17.3. Technology Type benchmarking
    • 8.4.17.4. Strategic initiatives
  • 8.4.18. Satori Cyber Ltd.
    • 8.4.18.1. Company overview
    • 8.4.18.2. Financial performance
    • 8.4.18.3. Technology Type benchmarking
    • 8.4.18.4. Strategic initiatives